Dosing Considerations

Pediatrics: The safety and effectiveness of MARINOL have not been established in pediatric patients. Pediatric patients may be more sensitive to neurological and psychoactive effects of MARINOL.

Geriatrics: Clinical studies of MARINOL in AIDS and cancer patients did not include the sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subject. Elderly patients may be more sensitive to the neuropsychiatric and postural hypotensive effects of the drug. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

Elderly patients with dementia are at increased risk for falls as a result of their underlying disease state which may be exacerbated by the central nervous system effects of somnolence and dizziness associated with MARINOL. These patients should be monitored closely and placed on fall precautions prior to initiating MARINOL therapy. In antiemetic studies, no difference in efficacy was apparent in patients >55 years old compared to younger patients.